Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Baxter Healthcare Corporation; Shire
- 13 Nov 2015 Results published in a Baxalta media release.
- 13 Nov 2015 The European Commission granted marketing authorization for Obizur in November 2015, according to a Baxalta media release.
- 15 Oct 2015 According to a Baxalta Inc. media release, Health Canada has approved Obizur for the treatment of bleeding episodes in patients with acquired haemophilia A. The approval was supported by the results of this trial.